Medical research

Expansion at Val de Reuil reinforces the company's position as a global leader in seasonal flu vaccines

As WHO warns the antibiotics pipeline does not address the threat of bacterial resistance, the EU must step up and do more to galvanise R&D, accelerate innovation and help shape a coordinated global response to the impending crisis

The University of Amsterdam (UvA)’s Faculty of Science, UvA Ventures Holding B.V. and Innovation Exchange Amsterdam (IXA-UvA) are pooling their resources to fund Macrobian Biotech BV, a single asset biotech company that will further develop medicine for the treatment of Parkinson’s disease.